GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud

 
• By Brenda Sandburg

GlaxoSmithKline’s $750 million settlement with the Department of Justice raises a worrisome question for industry: will violations of current good manufacturing practices become a target for whistleblower suits?

More from Archive

More from Pink Sheet